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Abstract
Introduction: Current methods for early diagnosis of osteoarthritis (OA) are limited. We assessed whether in vivo
detection of chondrocyte death by ApoPep-1 (CQRPPR), a peptide that binds to histone H1 of apoptotic and
necrotic cells, could be used to detect the initiation of OA.
Methods: Apoptosis-induced ATDC5 cells were labeled with Annexin V and ApoPep-1. Surgical destabilization of
the medial meniscus (DMM) was performed on both knees of 12-week-old male mice and severity of OA was
determined by histological analysis according to the Osteoarthritis Research Society International (OARSI) guidelines.
At 1, 2, 4, and 8 weeks post-surgery, mice were intravenously injected with fluorescence-labeled ApoPep-1 or
control peptide and in vivo imaging was performed within 30 minutes of injection by near-infrared fluorescence
(NIRF). Binding of ApoPep-1 to OA joints was demonstrated by ex vivo imaging and immunofluorescent staining
using TUNEL and histone H1 and type II collagen antibodies.
Results: Strong signals of ApoPep-1 were observed on the apoptotic ATDC5 cells. Knees corresponded to grade II,
III, and V OA at 2, 4, and 8 weeks after DMM, respectively. Between 2 and 8 weeks after surgery, the in vivo NIRF
signal at OA-ApoPep1-injected joints was consistently stronger than sham-operated or OA-control peptide-injected
joints. ApoPep-1, TUNEL, and histone H1 signals were stronger in grade II OA cartilage than sham-operated
cartilage when detected by immunofluorescent staining. Type II collagen expression was similar between grade II
OA and sham group.
Conclusion: ApoPep-1 can be used to detect OA in vivo by binding to apoptotic chondrocytes. This is a novel,
sensitive, and rapid method which can detect apoptotic cells in OA rodent models soon after its onset.
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Introduction
Osteoarthritis (OA), which affects more than 46.4 mil-
lion people in the USA, is characterized by gradual loss
of cartilage [1–3]. The current available treatment for
OA is joint replacement therapy, which is performed
when the cartilage is severely damaged [4]. This late-
stage OA is preceded by chronic pain and difficulty in
mobility [5, 6]. It is thought that non-surgical treatment
of OA is only possible during its early development, but
early detection of the disease is difficult due to the lack
of symptoms and affordable and sensitive detection
methods. Until further medical treatment techniques are
developed, diagnosis soon after the onset of OA is es-
sential to prevent irreversible cartilage degeneration and
deterioration and to promote cartilage recovery.
Current OA diagnosis methods have limitations for the
early detection during the onset of OA. The sensitivity of
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radiography is insufficient to detect the onset of OA. Radi-
ography can only examine joint space narrowing and
osteophytes, which are characteristics of advanced OA
[7]. Magnetic resonance imaging (MRI) provides high-
resolution computerized images of internal body tissue,
but is limited in its ability to detect articular chondrocyte
apoptosis, proteoglycans, and aggrecan loss, which are
characteristics of the initiation of OA. Loss of type II colla-
gen, an event that occurs in the early stages of OA devel-
opment [8, 9], is not detectable by MRI. Techniques for
diagnosing the onset of OA are necessary to prevent
chronic pain, prolonged difficulty in mobility, possible
complications due to joint replacement surgery, and
increased healthcare costs for the patient and society
[10, 11].
Detecting the amount of apoptotic articular chon-
drocytes may be a useful approach to diagnosis of OA,
because apoptosis occurs at an increased rate in the car-
tilage in OA compared to healthy cartilage [12, 13]. Ar-
ticular chondrocytes are important in maintaining the
dynamic equilibrium between synthesis and degradation
of the extracellular matrix [12–14]. Although subchon-
dral bone change has been postulated to be the first sign
of initiation of OA [15], articular change is also one of
the first to be affected by OA and its destruction can be
a warning sign of OA progression [15–19]. During the
early stages of OA, chondrocyte apoptosis increases in
the articular surface and middle zones of the cartilage,
probably as a consequence of constant mechanical dam-
age to the joint [20–22]. Apoptotic chondrocyte death
[23] has been reported to occur more frequently in
osteoarthritic cartilage than healthy cartilage in humans
and animals, and has been positively correlated with the
severity of cartilage damage in the joint [22, 24–26].
Apoptosis indicators include exposed cellular phosphati-
dylserine, dysfunctional mitochondria, activated caspases,
fragmented DNA, and disrupted membrane integrity
[27–29]. Annexin V, a 36 kDa protein that binds to
phosphatidylserine, is most commonly used and gener-
ally considered an early marker of apoptotic cell death in
vitro. However, annexin V also binds to type II collagen,
which is highly expressed in healthy articular cartilage
and facilitates the binding of chondrocytes to collagen
[30–33]. Therefore, annexin V would not be suitable
for distinguishing osteoarthritc cartilage from healthy
cartilage. On the other hand, caspase antibodies bind
to caspase enzymes to detect programmed cell death,
but these antibodies have slow binding kinetics, de-
layed clearance, and the possibility of immunogenicity.
These drawbacks require the development of a new
in vivo method to diagnose OA during its initial
stages.
Peptides have attractive potential to be used in diag-
nostic tools because of their many advantages, including
rapid binding kinetics and degradation, minimal concern
for immunogenicity, structural diversity, and attachabil-
ity to diverse probes [34–37]. Therefore, when used for
the diagnosis of OA, peptides may safely and accurately
detect osteoarthritic cartilage within a shorter time span
and be rapidly excreted from or degraded in the body.
Apoptosis-targeting Peptide-1 (ApoPep-1), a six-amino-
acid CQRPPR peptide, recognizes apoptotic and necrotic
cells by binding to histone H1 exposed on the surface of
these cells [38]. Histone H1, a linker histone which helps
stabilize chromatin fiber, is abundant in the nucleus but
is exposed on the cell membrane and released into the
extracellular matrix during apoptosis, thereby serving as
a unique and specific marker for cell death [39–41]. Use
of ApoPep-1 conjugated with fluorescent dye or isotopes
has been successful for in vivo imaging of apoptosis in
tumor cells and neurons [38, 42, 43].
In this study, we examined whether ApoPep-1 is ef-
fective in detecting OA during its early stage in vivo.
Destabilization of the medial meniscus (DMM) [44] was
performed on male mice and signals were assessed 2–8
weeks post-surgery.
Methods
Cell culture and immunocytochemistry
ATDC5 cells were maintained in a mixture of DMEM and
Ham’s F-12 medium (DMEM/F12) (Lonza, Walkersville,
MD, USA) containing 5 % fetal bovine serum (FBS; Gibco-
BRL, USA), 10 g/ml of human transferrin (Sigma, St. Louis,
MO, USA), 3 × 108 M of sodium selenite (Sigma), and
penicillin/streptomycin (Lonza). ATDC5 cells were plated
at a density of 1 × 105 cells/ml and apoptosis was induced
by incubating cells with 0.5 mM staurosporine (Sigma) for
6 hours. Cells were stained with annexin V (Santacruz,
Dallas, TX, USA) and FlammaTM 675 conjugated
ApoPep-1 (BioActs, Namdong-gu, Incheon, Korea) to
determine cell apoptosis. For immunocytochemistry, cells
were blocked in 1 % bovine serum albumin (BSA) at 37 °C
for 30 minutes and then for cell internalization samples
were soaked in 10 μM FlammaTM 675-conjugated peptide
at 4 °C for 1 hour. Cells were then co-stained with Alexa-
594-annexin V (Invitrogen, Carlsbad, CA, USA) for 15 mi-
nutes at room temperature (RT) in binding buffer (10 mM
HEPES, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2). After
fixation, cells were incubated with 4′, 6′ -diamidino-2-
phenylindole (DAPI, Sigma-Aldrich) to stain the nuclei.
Photos of the stained cells and differential interference
contrast (DIC) images were taken using a Zeiss LSM-510
Meta confocal microscope (Zeiss, Oberkochen, Germany)
using a plan apochromat 20×/0.8 numerical aperture.
Experimental animals
C57BL/6 N mice were purchased from KOATECH
(Gyeonggi-do, Korea), and animal care and experiments
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were carried out in accordance with the Institutional
Animal Care and Use Committee of Kyungpook National
University (KNU 2011-68). Animals were maintained on a
12-hour light/12-hour dark cycle at 22–25 °C in a specific
pathogen-free environment and fed standard rodent chow
and water ad libitum. Destabilization of the medial menis-
cus (DMM) surgery [44, 45] or sham surgery was per-
formed in a total of 49 male mice at 12 weeks of age. The
experimental scheme is shown in Fig. 1.
Assessment of OA
Three mice were sacrificed per time point at 2, 4, and
8 weeks after DMM surgery to assess the degree of OA.
An additional three mice were used as sham controls,
which were sacrificed 2 weeks after sham surgery. Hind
limbs of mice were fixed with 4 % paraformaldehyde
(PFA) in 0.1 M PBS for 12 hours and decalcified with
10 % ethylenediaminetetraacetic acid (EDTA; pH 7.4) for
3 weeks. Decalcified tissues were dehydrated by soaking
the samples in increasing concentrations of ethanol and
embedding in paraffin, and then were sectioned into a
thickness of 3 μm. For Safranin-O staining, sections
were deparaffinized, rehydrated, dipped in Weigert’s iron
hematoxylin (Sigma-Aldrich) for 10 minutes, in fast
green solution (Sigma) for 5 minutes, and in 0.1 %
Safranin-O solution (Sigma) for 5 minutes. Joints were
assessed for severity of OA according to the Osteoarth-
ritis Research Society International (OARSI) diagnosis
criteria [46]. Briefly, grade I and II denote that the super-
ficial zone remains intact, although there may be some
microscopic fibrillation and fissuring, and the middle
and deep zones are unaffected. Grade III changes appear
when vertical fissures extend into the middle zone, but
there is still no significant cartilage loss. Grade IV OA
develops when increased fissuring results in cartilage
erosion. Grade V and VI OA describe almost complete
erosion of the articular cartilage with changes affecting
the underlying bone, such as sclerosis [47].
In vivo and ex vivo optical imaging
Among the mice that underwent surgical DMM, half
were injected with FlammaTM675-ApoPep-1 (Bioacts)
and the other half with FlammaTM675-NSSSVDK (con-
trol peptide; Bioacts) through the tail vein (100 nmol/20 g
body weight) (n = 8/group). FlammaTM675-ApoPep-1
solution (1 mM) was diluted with PBS before the in-
jection. Sham-operated mice were also injected with
FlammaTM675-ApoPep-1 (n = 6). In vivo optical im-
aging was performed 0.5, 2.0, 4.0 and 12.0 hours after
probe administration using eXplore Optix (ART,
Montreal, QC, Canada) at 2 weeks after surgery, and
at 0.5 hours after injection at 1, 2, 4, and 8 weeks after
surgery. eXplore Optix measures fluorescent photons
following excitation by a picoseconds laser (laser pulse:
80 MHz). Mice were put under anesthesia by inhalation of
isoflurane (JW Pharmaceutical, Seoul, Korea) in 80 %
N2O/20 % O2 in the supine position and the field of view
for optical imaging was set manually in the joint or abdo-
men region of the mice. The excitation/emission wave-
lengths for FlammaTM675 were 676 nm/704 nm. Ex vivo
optical imaging was performed in extracted hind limbs
using the same method (n = 3/group).
Immunofluorescence staining
At 2 weeks post-operation (grade II OA), three mice per
group were sacrificed and knee joints were collected two
hours after injection of FlammaTM675-ApoPep1. The
joints were fixed with 4 % PFA in 0.1 M PBS for 12 hours
Fig. 1 Experimental scheme. Osteoarthritis was induced by surgical destabilization of the medial meniscus (DMM). Mice were divided into four
experimental groups: one that underwent in vivo imaging (n = 22) and three other groups that underwent ex vivo imaging, histology and
immunofluorescence analysis (n = 27). SA sham ApoPep-1 injection, DA DMM ApoPep-1 injection, DC DMM control-peptide injection, gp group
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and decalcified with 10 % EDTA (pH 7.4) for 3 weeks.
Samples were protected from light with aluminum foil.
Decalcified tissues were soaked in 20 % sucrose/PBS
solution overnight and embed in optimal cutting tem-
perature compound (OCT) (Tissue-Tek, Torrance, CA,
USA) and stored at –80 °C. Frozen samples were cut at
10 μm thickness from the femur to the tibia to visualize
the joint. Sections were washed with PBS, treated with
blocking solution (0.1 % tween-20, 1 % BSA), 5 % normal
donkey serum in PBS (Abcam, Cambridge, MA, USA)),
and then incubated at 4 °C for 1 hour with primary anti-
bodies (rabbit polyclonal collagen II antibody (1:200;
Abcam), rabbit polyclonal histone H1.2 (1:200; Santa
Cruz, CA, USA) and rabbit IgG (1:200; Abcam)).
Sections were incubated with Alexa-594- and Alexa-488-
conjugated secondary antibody for collagen type II and
histone H1.2, respectively, for 40 minutes. Thereafter, the
sections were incubated with DAPI for nuclei staining.
Photos of the stained sections were taken using a Zeiss
LSM-510 Meta confocal microscope (Zeiss) using a plan
apochromat 10×/0.45 numerical aperture.
TUNEL assay
TUNEL assay was conducted in the same joint samples
that were used for immunofluorescence. The ApopTag®
Red In Situ Apoptosis Detection Kit (Millipore, Billerica,
MA, USA) was used according to the manufacturer’s in-
structions. Frozen sections were air-dried for 30 minutes
at RT and washed three times with PBS for 3 minutes
each. The sections were pre-fixed with 1 % PFA for
10 minutes at RT, and then post-fixed by pre-cooled
ethanol/acetic acid (2:1) at –20 °C for 5 minutes. The
fixed tissue sections were incubated with DAPI for nu-
clei staining following exposure to equilibration buffer
for 10 seconds at RT and TdT enzymes for 30 minutes
at 37 °C. Photos of the stained sections were taken using
a Zeiss LSM-510 Meta confocal microscope (Zeiss).
Statistics
Statistical analyses were performed using Sigma Plot
software 10.0 (Systat Software Inc, Chicago, IL, USA).
Data are expressed as mean ± SD. Differences between
groups means were assessed by Student’s t test. P <0.05
was considered statistically significant.
Results
ApoPep-1 binds to apoptotic chondrocytes in vitro
To define the binding ability of ApoPep-1 to apoptotic
chondrocytes in vitro, we treated the ATDC5 chondro-
cyte cell line with staurosporine, which induces cell
apoptosis [48, 49]. In vitro fluorescence revealed that
strong signals of ApoPep-1 were observed on the cell
membrane, extracellular and cytosol of apoptotic cells,
but not on live cells (Fig. 2). Approximately 89 % of the
cells bound with annexin V were also bound to ApoPep-1.
However, ApoPep-1 and annexin V were not co-localized
ApoPep-1 DIC ImageDAPI














Fig. 2 ApoPep-1 binds to apoptotic chondrocytes. a ATDC5 cells were incubated with staurosporine (0.5 μM) for 6 hours to induce apoptosis
b ApoPep-1 binds to cells that bind to annexin V, a widely used in vitro marker for apoptosis. Cells were stained with ApoPep-1 (red), annexin V
(green), and 4′, 6′ -diamidino-2-phenylindole (DAPI) (blue). Differential interference contrast (DIC) microscopy. Magnification, ×400
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at the same spot on the apoptotic cells because ApoPep-1
binds to histone H1.2, whereas annexin V binds to phos-
phatidylserine, respectively. In these results we demon-
strated that ApoPep-1 detects apoptotic chondrocytes.
ApoPep-1 detects early stage OA in vivo
Given the in vitro results, we sought to determine
whether ApoPep-1 could be used to detect initiation of
OA using in vivo imaging. Sham-operated mice had
healthy cartilage surfaces with clear boundaries between
the cartilage and calcified bone surfaces 2 weeks post-
surgery. The pink stain (Safranin O) is an indicator of
proteoglycan, which is abundant in healthy cartilage.
The intensity of pink staining is proportional to proteo-
glycan content. The decreased intensity of Safranin O
with OA progression indicates loss of proteoglycan and
thus, damage to the cartilage over time after DMM. In
addition, the cartilage surface had severe degeneration
8 weeks post-surgery (Fig. 3a-b). However, joints of mice
that underwent surgical DMM matched the description
of grade II, III, and V OA at 2, 4, and 8 weeks post-
surgery, respectively, according to the OARSI diagnosis
criteria [46]. Diagnosis of OA is required at the latest by
the time grade III is reached, as OA up to grade III is
thought to have higher treatment efficacy and to be po-
tentially reversible [4, 50–53]. No signals were detected
in vivo in sham-operated mice and OA-model mice one
week after surgery. From 30 minutes to 12 hours post-
injection, a time-dependent decrease in fluorescent sig-
nals was detected when injected with ApoPep-1 at
2 weeks after DMM (grade II OA joints), but not in
sham- or control-peptide-injected DMM joints despite
the similar fluorescence signals of the peptides before in-
jection (Fig. 4a-b). Signals completely disappeared by
12 hours in the OA-ApoPep-1 mice. The signals were
specific to the joint and did not appear in other organs
at 30 minutes after injection (Fig. 4c). These results indi-
cate that ApoPep-1 specifically binds to joints with early
OA within a short time period after injection, and that
the peptide is rapidly excreted.
To monitor the progression of OA with ApoPep-1, we
assessed the strength of fluorescence at 1, 2, 4, and
8 weeks after surgery. Significantly stronger fluorescent
signals were observed in OA joints at 2 weeks post-
surgery and reached a peak at 4 weeks post-surgery in
the in vivo samples (Fig. 5a). The reduced signal strength
at 8 weeks post-DMM may be due to the absolute
decrease in apoptotic chondrocytes following articular
cartilage loss. Ex vivo near-infrared fluorescence (NIRF)
imaging of joints was performed after FlammaTM675-
ApoPep-1 injection also showed that the signals accu-
mulated in the joints of OA mice at 2 weeks post-
surgery and reached a peak at 4 weeks post-surgery, and
that there was reduced signal strength at 8 weeks post-
DMM (Fig. 5b). These results indicate that ApoPep-1 is




Fig. 3 Morphologic and histology analyses during osteoarthritis (OA) progression. a Morphology of the left proximal tibial cartilage of mice that
received sham operation or surgical destabilization of the medial meniscus (DMM). Eroded surfaces are seen within the yellow dotted lines.
b Histomorphometry of joints in sham-operated and mice that underwent DMM, shown by Safranin O staining. c Mean Osteoarthritis Research Society
International (OARSI) scores for joints for indicated surgery/time points (n = 3/group). Values are mean ± SD. A anterior, P posterior, wks weeks
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stage OA, though signal strength may not correlate with
OA damage.
In situ assessment of ApoPep-1 in joints
Grade II OA joints were analyzed by in situ immunofluor-
escence staining to confirm the correlation of ApoPep-1
and cell death in cartilage at 2 weeks post-operation.
Through immunofluorescence, strong signals of both
ApoPep-1 and TUNEL were observed on the cell surface
and extracellular matrix of OA joints (Fig. 6a). No signal
was detected in sham articular cartilage. Fluorescence
from FlammaTM675-ApoPep-1 was observed in OA
joints at locations similar to but also deeper in the ar-
ticular cartilage than histone H1 (Fig. 5b). ApoPep-1 was
specifically accumulated in the articular cartilage but not
in the subchondral bone or synovium tissues. Type II
collagen expression was similar between the sham and
OA mice articular cartilage, whereas strong ApoPep-1 sig-
nals were detected in the OA cartilage, indicating that
ApoPep-1 can bind to cartilage before loss of type II colla-
gen (Fig. 7). These in situ results suggest that ApoPep-1
can detect apoptotic chondrocytes through binding to
histone H1 at early stages of OA, before loss of type
II collagen is detected.
Discussion
In this study, we found that the ApoPep-1 probe clearly
detected surgically induced OA from its initiation (grade
II) up to late-stage OA (grade V) on in vivo imaging. An
ideal method should detect OA as early as possible, be
rapidly accumulated in high concentrations in knee joints,
and rapidly cleared from the system [47]. ApoPep-1 binds
A
B C
Fig. 4 Osteoarthritis (OA) initiation is detected using ApoPep-1 within 30 minutes of injection. Destabilization of the medial meniscus or sham
surgery was performed in both knees of the mice at 12 weeks of age and mice were scanned in the supine position 2 weeks after surgery. Purple
boxes indicate region of scan. a ApoPep-1 was detected in joints of OA mice (2 weeks after surgery) from 0.5 hours to 4.0 hours after intravenous
injection. Signals disappeared by 12 hours. Photo of one representative mouse for each group. Quantified mean ± SD is shown for each group
(arbitrary units). b Fluorescence is detected in the joints of OA mice injected with ApoPep-1, but not in other organs, sham mice, or mice injected
with the control peptide. Photo of one representative mouse for each group. Sham-ApoPep-1 sham operation and Apo-Pep-1 injection (n = 6),
OA-Control OA operation and control peptide injection (n = 8), OA-ApoPep-1 OA operation and ApoPep-1 injection (n = 8), NC normalized count.
Values are mean ± SD; *p <0.01 OA-ApoPep-1 compared to Sham-ApoPep-1, #p <0.01 OA-ApoPep-1 compared to OA-Control. c Fluorescence
intensity (arbitrary units) of ApoPep-1 and control peptide were similar before injection. PC proton count
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Fig. 5 Assessment of osteoarthritis (OA) progression using the ApoPep-1 probe. a In vivo optical images 30 minutes after intravenous injection of
ApoPep-1 or control probe at different stages of OA development (1, 2, 4, and 8 weeks after destabilization of the medial meniscus (DMM) or
sham operation). Photo of one representative mouse for each group. Quantified mean ± SD are shown for each group (arbitrary units): Sham-ApoPep-1
sham operation and Apo-Pep-1 injection (n = 6), OA-Control OA operation and control peptide injection (n = 8), OA-ApoPep-1 OA operation and
ApoPep-1 injection (n = 8), wks weeks. b Ex vivo optical images of mouse joints 2 hours after intravenous injection of ApoPep-1 at different stages of
OA development (2, 4, and 8 weeks after sham operation or DMM) (n = 3/group). Quantified mean ± SD are shown for each group (arbitrary units);
*p <0.05 OA-ApoPep-1 compared to Sham-ApoPep-1, #p <0.05 OA-ApoPep-1 compared to OA-Control. NC normalized count
A
B
Fig. 6 ApoPep-1 binds to grade II osteoarthritis (OA) cartilage. Joints were harvested and cryo-sectioned 2 weeks after sham operation or surgical
destabilization of the medial meniscus. ApoPep-1 was injected intravenously before harvest. a Strong signals of ApoPep-1 and TUNEL both appear
in grade II OA joints, but not in sham-operated joints. b ApoPep-1 and histone H1 appear in OA cartilage, but not sham-operated cartilage. Scale
bar 50 μm. DAPI 4′, 6′ -diamidino-2-phenylindole
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to grade II OA joints before loss of type II collagen, but
not to healthy joints, and as early as 30 minutes post-
injection. We observed higher type II collagen signals in
the grade II OA cartilage compared to sham-operated
cartilage.
In humans, chondrocytes in OA cartilage are reported
to form clusters, which increase in size with OA pro-
gression [54]. These events may lead to aggregation of
type II collagen in the cartilage and result in the stronger
signals of type II collagen seen in our mice, confirming
the initiation of OA. We did not find any signals in
other organs, although other organs, such as the intes-
tine, have rapid cell turnover rate and a large amount of
apoptosis occurs. As the fluorescence intensity was nor-
malized to eliminate background and auto fluorescence,
fluorescent signals from other organs were dampened or
disappeared while the strong signals at the OA joints
were clearly detected. ApoPep-1 has been previously re-
ported to be cleared from the system through the kidney
within 4 hours of injection and did not accumulate in
the liver and lung [38]. These results indicated that
ApoPep-1 is optimal for use in vivo even when bound to
materials with possible health risks following prolonged
exposure, such as radioisotopes.
The rapid and highly concentrated binding of ApoPep-1
to OA joints shows that ApoPep-1 is an effective tool to
detect OA during the early stages. The binding site of
ApoPep-1 differs from that of annexin V and TUNEL in
the apoptotic cells and OA tissues, respectively. Although
both ApoPep-1 and annexin V were present on the sur-
face of apoptotic ATDC5 cells in vitro, the specific binding
sites did not always coincide. ApoPep-1 binds to histone
H1.2, whereas annexin V binds to phosphatidylserine.
Similarly, TUNEL staining, which detects fragmented
DNA, appeared within the cell nucleus of the tissue,
whereas ApoPep-1 was found on the cell surface and
within the articular cartilage matrix. Histone H1 has been
reported to be released into the extracellular matrix dur-
ing apoptosis [39–41, 55]. On the other hand, the binding
sites of histone H1 antibody and ApoPep-1 signals were
similar in the articular cartilage but ApoPep-1 penetrated
deep into the cartilage matrix despite being injected in
vivo before preparation for immunofluorescence. ApoPep-
1 may bind to other factors within OA cartilage once
bound to damaged cartilage, but this still needs to be elu-
cidated. Nonetheless, ApoPep-1, annexin V, TUNEL, and
histone H1 antibody all bound to grade II OA joints, but
not sham-operated joints.
Fig. 7 ApoPep-1 binds to grade II osteoarthritis (OA) cartilage before loss of type II collagen. ApoPep-1 was injected 2 weeks after sham operation
or surgical destabilization of medial meniscus (DMM) and joints were harvested. The joints were cryo-sectioned and stained for 4′, 6′ -diamidino-
2-phenylindole (DAPI, blue) and Collagen 2 (red). Yellow ApoPep-1. Scale bar 50 μm
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ApoPep-1 has many strengths for its use in vivo. Re-
cently, enhanced T1ρ-weighted MRI has been reported
to measure biochemical composition and changes in
proteoglycan content in articular cartilage during the
initiation of OA [56]. However, MRI scanners are very
expensive for general use (especially for the preventative
use in those without symptoms), noisy, and may cause
claustrophobia during the scan. MRI scans are also
inappropriate for patients with cardiac pacemakers or
other metal implants, which are not uncommon in the
older population. The use of ApoPep-1 to detect OA is
more affordable and easily generalizable than MRI.
Moreover, ApoPep-1 can be easily synthesized and opti-
mized, has no serious immune responses, and is rapidly
cleared from the system. ApoPep-1 is non-toxic and
does not accumulate in specific organs, which can
minimize possible side effects of markers conjugated to
ApoPep-1 (such as fluorescent dyes, radioactive isotopes,
etc). The use of fluorescent probes conjugated with
ApoPep-1 may be limited for detection of OA in
humans. The eXplore Optix detects nanomolar concen-
trations of fluorescent signals at depths of 5–8 mm in
mouse tissue. Thus, the thicker depth of skin and muscle
in humans will hinder the detection of fluorescence sig-
nals transmitted from the ApoPep-1 probe in OA joints.
For use in humans, ApoPep-1 may be conjugated with
radioisotopes, while fluorescent probes may be more
economical for in vivo OA research using surgically
induced OA rodent models. In the future, ApoPep-1
conjugated with anti-apoptotic drugs may be used for
targeted OA drug delivery.
One limitation of our study is that we did not test
whether ApoPep-1 distinguishes OA from other joint
diseases, such as rheumatoid arthritis (RA). However,
the clinical symptoms differ between RA and OA, and
do not necessarily need to be differentiated from each
other by in vivo imaging. In addition, ApoPep-1 may not
be used to monitor OA progression or treatment effects.
Though OA joints had higher fluorescent signals than
sham-operated joints, the degree of OA did not correlate
with the strength of fluorescence, especially during later
stages of OA, possibly due to the absolute loss of chon-
drocytes in advanced OA. However, the loss of chondro-
cytes and cartilage at this stage can be detected by MRI.
The use of ApoPep-1 in humans must first be evaluated,
as apoptosis occurs slowly in natural OA in humans.
Acute conditions of high apoptosis following exercise or
other stress-related conditions may lead to the misdiag-
nosis of OA. Therefore, for future application in clinical
settings, patients will need to be counseled several days
before the use of ApoPep-1. Still, our results indicate
that ApoPep-1 is suitable for in vivo OA research during
initiation of the disease, when using surgically induced
OA rodent models.
Conclusion
The ApoPep-1 probe facilitates the detection of OA as
early as 2 weeks after DMM in mouse models (grade II
OA) by specifically detecting apoptotic chondrocytes
within 30 minutes. The present study is the first to
detect initiation of OA in vivo during its potentially re-
versible period. ApoPep-1 is a potentially safe, effective,
cost-effective and time-efficient method for the early de-
tection of OA in rodent models.
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